Abstract: Proteinaceous bioactive substances (including lymphokine and peptide hormone) in dry solid are extremely stabilized by the presence of the specific polysaccharide mainly composed of repeating maltotriose units. Pullulan, elsinan, and their partial hydrolysates are feasible as the polysaccharide. The weight ratio of the polysaccharide to the substance which effectively stabilizes the latter substance is at least 0.5 on the basis of dry solids. The dry solid is advantageously usable as a test reagent, injection, granule, tablet, suppository or ointment.

Abstract: The present invention relates to a process for the production of anti-human protein antibody, comprising induction of the antibody production in non-human warm-blooded animal cells capable of producing said antibody by injecting into a non-human warm-blooded animal a human protein-saccharide conjugate, obtained by covalent attachment of a human protein with a saccharide, and harvesting the resulting anti-human protein antibody. The antibody, prepared according to the invention, contains an extremely higher amount of immunoglobulin G than that obtained by conventional method while it contains slight or substantially no immunoglobulin E. Therefore, the antibody can be used advantageously for diagnostic, prophylactic or therapeutic administration in the prevention and treatment of human diseases.

Abstract: The present invention relates to a process for the production of virus vaccine, comprising covalently attaching virus to saccharide to form a virus-saccharide conjugate, and harvesting the resultant conjugate. The virus vaccine, prepared according to the present invention, exhibits a higher producibility of immunoglobulin G and immunoglobulin M antibodies, while it induces less or substantially no production of immunoglobulin E antibody, in comparison with conventional-type inactivated virus vaccine; thus, the present vaccine is favorably usable for the prevention and treatment of viral diseases.

Abstract: The present invention relates to a process for the production of anti-human protein antibody, comprising induction of the antibody production in non-human warm-blooded animal cells capable of producing said antibody by injecting into a non-human warm-blooded animal a human protein-saccharide conjugate, obtained by covalent attachment of a human protein with a saccharide, and harvesting the resulting anti-human protein antibody. The antibody, prepared according to the invention, contains an extremely higher amount of immunoglobulin G than that obtained by conventional method while it contains slight or substantially no immunoglobulin E. Therefore, the antibody can be used advantageously for diagnostic, prophylactic or therapeutic administration in the prevention and treatment of human diseases.

Abstract: The present invention relates to a process for the production of vaccine, characterized by covalent attachment of a biologically toxic substance to a saccharide both to form a biologically toxic substance-saccharide conjugate and to detoxify said substance, followed by collection of the formed conjugate. According to the invention, various vaccine products having a high productivity of immunoglobulin G and M antibodies, but without productivity of immunoglobulin E antibody, are easily obtainable. In addition, the vaccine products, upon administration to animals, do not effect any allergic reaction and/or anaphylactic-shock due to the lack of the immunoglobulin E antibody production.